Hong Kong-headquartered AI-driven drug discovery startup Insilico Medicine said Friday that it has dosed 80 healthy volunteers in a Phase I clinical trial to evaluate the safety of a drug candidate generated by the company’s AI-powered drug discovery platform to cure idiopathic pulmonary fibrosis
Read more: https://bit.ly/35hSg89